Brief: Brainstorm Cell Therapeutics Received Letter From Nasdaq Indicating Co Had Not Regained Compliance With Minimum Bid Price Requirement By April 29
03/05/2024 21:30
May 3 (Reuters) - Brainstorm Cell Therapeutics Inc
BCLI.O :
* BRAINSTORM CELL THERAPEUTICS: RECEIVED LETTER FROM NASDAQ
INDICATING CO HAD NOT REGAINED COMPLIANCE WITH MINIMUM BID PRICE
REQUIREMENT BY APRIL 29
Source text for Eikon: ID:n0001104659-24-056971
Further company coverage: BCLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview